RecruitingPhase 1NCT06799013
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
Studying Crimean-Congo hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- HDT Bio
- Principal Investigator
- Malcolm Duthie, PhDHDT Bio
- Intervention
- 10 ug HDT 321(biological)
- Enrollment
- 48 enrolled
- Eligibility
- 18-64 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Flourish Research San Antonio (Clinical Trials of Texas), San Antonio, Texas, United States
Collaborators
DFNet Research Inc. · Technical Resources International, Inc. (TRI) · BioAgilytix Labs, LLC · The University of Texas Medical Branch, Galveston · Clinical Trials of Texas, Inc. · Quest Laboratories
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06799013 on ClinicalTrials.gov